Full DNA testing in 50 Brazilian people with neurofibromatosis type 1
Original title: Whole-genome sequencing in Brazilian patients with neurofibromatosis type 1, including novel variants, incidental findings, and dual diagnoses.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This study only looked at exams and DNA results from patients, not at a treatment.
The short version
A full DNA test found the cause of this condition in nearly every family checked.
What was studied. Doctors looked back at records for 50 people from 30 unrelated families in Brazil who had signs of neurofibromatosis type 1. Each person had a medical exam and a test that reads their whole DNA.
What they found. Ages ranged from 9 months to 62 years. Flat brown skin patches, called cafe-au-lait spots, were found in 100% of patients, and freckle-like spots in 94%. All of the main patients tested, except one, had a DNA change known or likely to cause the condition, and three of those changes had never been reported before. Eight people had tumors other than neurofibromas, including two with malignant peripheral nerve sheath tumors and two with breast cancer.
What this means, and what it doesn't
What it could mean: For most people with signs of this condition, a full DNA test can find the change that explains it. The test can also point to other health risks in a family that no one knew about. Some people turned out to have a second, separate genetic condition as well.
What it doesn't mean: This does not mean a new treatment. No drug or therapy was tested here. Doctors only looked back at exams and DNA results that had already been collected. It says nothing about living longer or feeling better, and it is not a cure for this condition. It also does not mean your own results would look like these. This was one group of families in Brazil.
Source: PubMed, July 24, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.